These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification. Dottermusch M; Schüller U; Hagel C; Saeger W Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335 [TBL] [Abstract][Full Text] [Related]
5. Overview of the 2022 WHO Classification of Pituitary Tumors. Asa SL; Mete O; Perry A; Osamura RY Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028 [TBL] [Abstract][Full Text] [Related]
6. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features. Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887 [TBL] [Abstract][Full Text] [Related]
7. Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors. Silva-Ortega S; García-Martinez A; Niveiro de Jaime M; Torregrosa ME; Abarca J; Monjas I; Picó Alfonso A; Aranda López I Hum Pathol; 2021 Apr; 110():20-30. PubMed ID: 33321163 [TBL] [Abstract][Full Text] [Related]
9. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Neou M; Villa C; Armignacco R; Jouinot A; Raffin-Sanson ML; Septier A; Letourneur F; Diry S; Diedisheim M; Izac B; Gaspar C; Perlemoine K; Verjus V; Bernier M; Boulin A; Emile JF; Bertagna X; Jaffrezic F; Laloe D; Baussart B; Bertherat J; Gaillard S; Assié G Cancer Cell; 2020 Jan; 37(1):123-134.e5. PubMed ID: 31883967 [TBL] [Abstract][Full Text] [Related]
10. TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT. Yao H; Xie W; Dai Y; Liu Y; Gu W; Li J; Wu L; Xie J; Rui W; Ren B; Xue L; Cheng Y; Lin S; Li C; Tang H; Wang Y; Lou M; Zhang X; Hu R; Shang H; Huang J; Wu ZB Neuro Oncol; 2022 Aug; 24(8):1286-1297. PubMed ID: 35218667 [TBL] [Abstract][Full Text] [Related]
11. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Mete O; Asa SL Endocr Pathol; 2020 Dec; 31(4):330-336. PubMed ID: 32813227 [TBL] [Abstract][Full Text] [Related]
12. Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience. Mihajlović M; Pekić S; Doknić M; Stojanović M; Rašić D; Miljić D; Petakov M; Manojlović Gačić E Int J Surg Pathol; 2024 May; 32(3):470-477. PubMed ID: 37438981 [No Abstract] [Full Text] [Related]
13. Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours. Øystese KAB; Casar-Borota O; Berg-Johnsen J; Berg JP; Bollerslev J Endocrine; 2022 Jun; 77(1):151-159. PubMed ID: 35674926 [TBL] [Abstract][Full Text] [Related]
14. [New pathological classification and clinical implications of pituitary neuroendocrine tumors of the 2022 WHO version]. Xie J; Wu ZB Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(47):3723-3726. PubMed ID: 36517420 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Correlates of PIT1 and SF1-Multilineage Pituitary Neuroendocrine Tumors and the Diagnostic Utility of NKX2.2 Immunohistochemistry in Pituitary Pathology. Doğukan FM; Karatay H; Yüzkan S; Burhan Ş; Erkan B; Yılmaz-Özgüven B Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38649148 [TBL] [Abstract][Full Text] [Related]